Cagrilintide
Long-acting amylin analog: enhances satiety, designed to stack with semaglutide (CagriSema).
- Typical dose
- 300 mcg – 2.4 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 7.66667 days
- Routes
- Subcutaneous
- Status
- Investigational
Benefits
- Enhanced satiety
- Weight loss
- Synergy with semaglutide
Dosing
A common research range for Cagrilintide is 300 mcg to 2.4 mg once weekly. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Cagrilintide has an approximate half-life of 7.66667 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C.
Reported side effects
- Nausea
- Injection site reactions
Commonly stacked with
Track Cagrilintide with Vial
Vial logs every Cagrilintide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Cagrilintide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.